REFERENCES
- Andre F.E., Booy R., Bock H.L., Clemens J., Datta S.K., John T.J., Lee B.W., Lolekha S., Peltola H., Ruff T.A., Santosham M., Schmitt H.J. (2008) Bulletin of the World Health Organization, 86, 140–146.
- Beutels P. (2001) Health Econ., 10(8), 751–774.
- Beutels P., Edmunds W.J., Antoñanzas F., de Wit G.A., Evans D., Feilden R., Fendrick A.M., Ginsberg G.M., Glick H.A., Mast E., Péchevis M., van Doorslaer E.K.A., van Hout B.A. (2002) PharmacoEconomics, 20(1), 1–7.
- Bloom B.S., Hillman A.L., Fendrick A.M., Schwartz J.S. (1993) Ann. Intern. Med., 118, 298–306.
- Drummond M., Chevat C., Lothgren M. (2007) Vaccine, 25, 5945–5957.
- Ehreth J. (2003) Vaccine, 21, 4112.
- Goldstein S.T., Alter M.J., Williams I.T., Moyer L.A., Judson F.N., Mottram K., Fleenor M., Ryder P.L., Margolis H.S. (2002) J. Infect. Dis., 185, 713–719.
- Jacobs R.J., Meyerhoff A.S. (2004) J. Adolescent Health, 34(5), 420–423.
- Kao J-H., Chen D-S. (2002) The Lancet Infectious Diseases, 2(7), 395–403.
- Krahn M., Detsky A.S. (1993) Med. Decis. Making, 13, 4–20.
- Lahaye D., Baleux C., Strauss P., Van Ganse W. (1987) The Lancet, 330(8556), 441–443.
- Lavanchy D. (2004) J. Viral Hepat., 11(2), 97–107.
- Levine R. (2003) In: The Vaccine Book (Bloom B.R., P.H. Lambert, Eds.), Academic Press, San Diego, 23–35.
- Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., Zhang Y., Liu J., Gong X., Chen Y., Wang F., Zheng H., Wang F., Guo J., Jia Z., Ma J., Wang H., Luo H., Li L., Jin S., Hadler S.C., Wang Y. (2009) J. Infect. Dis., 200, 39–47.
- Mangtani P., Hall A.J., Normand C.E. (1995) Epidemiol. Community Health, 49, 238–244.
- Ministry of Health. Positive Dug List Committee and Pricing Committee Registries, www.mg.government.bg (In Bulgarian)
- Mitkov Tz., Tzenova A., Danchev N., Petrova G. (2004) Arch. Farm., 54, 823–841.
- NHIF (2010) National Framework Contracts 1989–2010, www.nhif.bg (In Bulgarian)
- Nichol K.L. (2001) Arch. Intern. Med., 161, 749–759.
- Plotkin S.L., Plotkin S.A. (2004) In: Vaccines, 4th Ed. (S.A. Plotkin, W.A. Orenstein, Eds.), WB Saunders, Philadelphia, 1–15.
- Rascati K.L. (2009) Essential of Pharmacoeconomics, Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York, London, pp. 89–109.
- U.S. Centers for Disease Control and Prevention (2003) MMWR (Morbidity and Mortality Weekly report), 52(36), 868–870.
- Van Damme P., Tormans G., Beutels P., Van Doorslaer E. (1992) Vaccine, 13(1),S54–S57.
- Viral Hepatitis Prevention Board (2011) Meetings and Publications, Presentations, Treatment and laboratory monitoring of chronic hepatitis patients in Bulgaria, March 2011, www.vhph.org
- WHO (1992) Expanded Programme on Immunization, Global Advisory Group—part I. Wkly Epidemiol. Rec., 67(3), 11–15.
- Zuckerman J., van Hattum J., Cafferkey M., Gjørup I., Hoel T., Rummukainen M-L., Weiland O. (2007) The Lancet Infectious Diseases, 7(6), 410–419.